Abstract
Atherosclerosis is widely regarded as a chronic inflammatory disease that develops as a consequence of entrapment of low-density lipoprotein (LDL) in the arterial intima. Native LDL lacks inflammatory properties, so the lipoprotein must undergo biochemical alterations to become atherogenic. Among several other candidates, two different concepts of lipoprotein modification are propagated, the widespread oxidation hypothesis and the less common E-LDL hypothesis, which proposes that modification of LDL occurs through the action of ubiquitous hydrolytic enzymes (enzymatically modified LDL or E-LDL) rather than oxidation. By clearly distinguishing between the initiation and progression of atherosclerotic lesion development, this article reviews comparative studies of both types of lipoprotein modification and submits a viewpoint for discussion proposing that these lipoprotein modifications do not really compete, but rather complement one another. According to this concept, E-LDL might be more important for the initiation of atherosclerosis, while oxidative modification of LDL might be more helpful for diagnosis and prognosis of the disease.
Clin Chem Lab Med 2006;44:1389–94.
References
1. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340:115–26.10.1056/NEJM199901143400207Search in Google Scholar
2. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9:471–4.10.1097/00041433-199810000-00012Search in Google Scholar
3. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272:20963–6.10.1074/jbc.272.34.20963Search in Google Scholar
4. Bhakdi S, Lackner KJ, Han SR, Torzewski M, Husmann M. Beyond cholesterol: the enigma of atherosclerosis revisited. Thromb Haemost 2004; 91:639–45.10.1160/TH03-12-0733Search in Google Scholar
5. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915–24.Search in Google Scholar
6. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85:1260–6.10.1172/JCI114562Search in Google Scholar
7. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990; 87:5134–8.10.1073/pnas.87.13.5134Search in Google Scholar
8. Terkeltaub R, Banka CL, Solan J, Santoro D, Brand K, Curtiss LK. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb 1994; 14:47–53.10.1161/01.ATV.14.1.47Search in Google Scholar
9. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 2000; 247:371–80.10.1046/j.1365-2796.2000.00656.xSearch in Google Scholar
10. Maseri A, Fuster V. Is there a vulnerable plaque? Circulation 2003; 107:2068–71.10.1161/01.CIR.0000070585.48035.D1Search in Google Scholar
11. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 2004; 13:125–38.10.1016/S1054-8807(04)00004-3Search in Google Scholar
12. Madjid M, Zarrabi A, Litovsky S, Willerson JT, Casscells W. Finding vulnerable atherosclerotic plaques: is it worth the effort? Arterioscler Thromb Vasc Biol 2004; 24:1775–82.10.1161/01.ATV.0000142373.72662.20Search in Google Scholar
13. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86:1372–6.10.1073/pnas.86.4.1372Search in Google Scholar
14. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84:1086–95.10.1172/JCI114271Search in Google Scholar
15. Shaw PX, Horkko S, Tsimikas S, Chang MK, Palinski W, Silverman GJ, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 2001; 21:1333–9.10.1161/hq0801.093587Search in Google Scholar
16. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 1999; 6:41–53.10.1016/S1071-3581(99)90064-8Search in Google Scholar
17. Tsimikas S, Shortal BP, Witztum JL, Palinski W. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 2000; 20:689–97.10.1161/01.ATV.20.3.689Search in Google Scholar
18. Torzewski M, Shaw PX, Han KR, Shortal B, Lackner KJ, Witztum JL, et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol 2004; 24:2307–12.10.1161/01.ATV.0000149378.98458.feSearch in Google Scholar
19. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100:2680–90.10.1172/JCI119813Search in Google Scholar
20. Calara F, Dimayuga P, Niemann A, Thyberg J, Diczfalusy U, Witztum JL, et al. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 1998; 18:884–93.10.1161/01.ATV.18.6.884Search in Google Scholar
21. Kruth HS. Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin-positive, oil-red-O-negative particles. Am J Pathol 1984; 114:201–8.Search in Google Scholar
22. Kruth HS. Subendothelial accumulation of unesterified cholesterol. An early event in atherosclerotic lesion development. Atherosclerosis 1985; 57:337–41.10.1016/0021-9150(85)90045-0Search in Google Scholar
23. Sakurada T, Orimo H, Okabe H, Noma A, Murakami M. Purification and properties of cholesterol ester hydrolase from human aortic intima and media. Biochim Biophys Acta 1976; 424:204–12.10.1016/0005-2760(76)90189-2Search in Google Scholar
24. Hakala JK, Oksjoki R, Laine P, Du H, Grabowski GA, Kovanen PT, et al. Lysosomal enzymes are released from cultured human macrophages hydrolyze LDL in vitro and are present extracellularly in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2003; 23:1430–6.10.1161/01.ATV.0000077207.49221.06Search in Google Scholar PubMed
25. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18:369–78.10.1161/01.ATV.18.3.369Search in Google Scholar
26. Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum-Jensen J, et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182:1959–71.10.1084/jem.182.6.1959Search in Google Scholar PubMed PubMed Central
27. Kapinsky M, Torzewski M, Buchler C, Duong CQ, Rothe G, Schmitz G. Enzymatically degraded LDL preferentially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class B scavenger-receptor CD36. Arterioscler Thromb Vasc Biol 2001; 21:1004–10.10.1161/01.ATV.21.6.1004Search in Google Scholar
28. Kruth HS, Zhang WY, Skarlatos SI, Chao FF. Apolipoprotein B stimulates formation of monocyte-macrophage surface-connected compartments and mediates uptake of low density lipoprotein-derived liposomes into these compartments. J Biol Chem 1999; 274:7495–500.10.1074/jbc.274.11.7495Search in Google Scholar PubMed
29. Seifert PS, Hugo F, Tranum-Jensen J, Zahringer U, Muhly M, Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990; 172:547–57.10.1084/jem.172.2.547Search in Google Scholar PubMed PubMed Central
30. Suriyaphol P, Fenske D, Zahringer U, Han SR, Bhakdi S, Husmann M. Enzymatically modified nonoxidized low-density lipoprotein induces interleukin-8 in human endothelial cells: role of free fatty acids. Circulation 2002; 106:2581–7.10.1161/01.CIR.0000038366.11851.D0Search in Google Scholar PubMed
31. Dersch K, Ichijo H, Bhakdi S, Husmann M. Fatty acids liberated from low-density lipoprotein trigger endothelial apoptosis via mitogen-activated protein kinases. Cell Death Differ 2005; 12:1107–14.10.1038/sj.cdd.4401633Search in Google Scholar PubMed
32. Torzewski M, Suriyaphol P, Paprotka K, Spath L, Ochsenhirt V, Schmitt A, et al. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler Thromb Vasc Biol 2004; 24:2130–6.10.1161/01.ATV.0000144016.85221.66Search in Google Scholar PubMed
33. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006; 113:2128–34; discussion 51.10.1161/CIRCULATIONAHA.105.611350Search in Google Scholar PubMed
34. Jialal I, Devaraj S, Venugopal SK. C-Reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44:6–11.10.1161/01.HYP.0000130484.20501.dfSearch in Google Scholar PubMed
35. Verma S, Szmitko PE, Yeh ET. C-Reactive protein: structure affects function. Circulation 2004; 109:1914–7.10.1161/01.CIR.0000127085.32999.64Search in Google Scholar PubMed
36. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18:1386–92.10.1161/01.ATV.18.9.1386Search in Google Scholar PubMed
37. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19:2348–54.10.1161/01.ATV.19.10.2348Search in Google Scholar
38. Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 1989; 60:747–54.Search in Google Scholar
39. Schmiedt W, Kinscherf R, Deigner HP, Kamencic H, Nauen O, Kilo J, et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18:1790–5.10.1161/01.ATV.18.11.1790Search in Google Scholar
40. Torzewski M, Torzewski J, Bowyer DE, Waltenberger J, Fitzsimmons C, Hombach V, et al. Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997; 17:2448–52.10.1161/01.ATV.17.11.2448Search in Google Scholar PubMed
41. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 1996; 16:673–7.10.1161/01.ATV.16.5.673Search in Google Scholar
42. Bhakdi S, Torzewski M, Paprotka K, Schmitt S, Barsoom H, Suriyaphol P, et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004; 109:1870–6.10.1161/01.CIR.0000124228.08972.26Search in Google Scholar PubMed
43. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192:1353–64.10.1084/jem.192.9.1353Search in Google Scholar PubMed PubMed Central
44. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006; 113:2135–50; discussion 50.Search in Google Scholar
45. Torzewski J. C-Reactive protein and atherogenesis: new insights from established animal models. Am J Pathol 2005; 167:923–5.10.1016/S0002-9440(10)61182-0Search in Google Scholar
46. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-Reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002; 99:13043–8.10.1073/pnas.192399699Search in Google Scholar PubMed PubMed Central
47. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999; 103:117–28.10.1172/JCI4533Search in Google Scholar PubMed PubMed Central
48. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105:1731–40.10.1172/JCI8472Search in Google Scholar PubMed PubMed Central
49. Zwaka TP, Hombach V, Torzewski J. C-Reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103:1194–7.10.1161/01.CIR.103.9.1194Search in Google Scholar PubMed
50. Wieland E, Dorweiler B, Bonitz U, Lieser S, Walev I, Bhakdi S. Complement activation by oxidatively modified low-density lipoproteins. Eur J Clin Invest 1999; 29:835–41.10.1046/j.1365-2362.1999.00548.xSearch in Google Scholar PubMed
51. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99:993–8.10.1161/01.CIR.99.8.993Search in Google Scholar
52. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84:1381–478.10.1152/physrev.00047.2003Search in Google Scholar PubMed
53. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92:8264–8.10.1073/pnas.92.18.8264Search in Google Scholar PubMed PubMed Central
54. Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997; 150:1687–99.Search in Google Scholar
55. Rajavashisth T, Qiao JH, Tripathi S, Tripathi J, Mishra N, Hua M, et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. J Clin Invest 1998; 101:2702–10.10.1172/JCI119891Search in Google Scholar PubMed PubMed Central
©2006 by Walter de Gruyter Berlin New York
